Lupin is currently trading at Rs. 2034.80, down by 16.50 points or 0.80% from its previous closing of Rs. 2051.30 on the BSE.
The scrip opened at Rs. 2039.95 and has touched a high and low of Rs. 2057.00 and Rs. 2016.80 respectively. So far 18567 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 2403.45 on 02-Jan-2025 and a 52 week low of Rs. 1774.00 on 07-Apr-2025.
Last one week high and low of the scrip stood at Rs. 2063.60 and Rs. 1974.25 respectively. The current market cap of the company is Rs. 92881.03 crore.
The promoters holding in the company stood at 46.90%, while Institutions and Non-Institutions held 46.81% and 6.28% respectively.
U.S. Food and Drug Administration (USFDA) has concluded an inspection at Lupin’s Nagpur Injectable facility. USFDA has conducted the said inspection from September 08 to September 16, 2025. The inspection closed with six observations.
The company will address the observations and respond to the U.S. FDA within the stipulated timeframe. The company is committed to be compliant with CGMP quality standards across all its facilities.
Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.
